Major Innovation in Site Feasibility to Launch at SCOPE 2014
At this year's annual SCOPE in Miami, data management and information services provider, Infinata, Inc., will unveil SiteSurvey
At this year’s annual Summit for Clinical Operations Executives (SCOPE) in Miami, data management and information services provider, Infinata, Inc., will unveil SiteSurvey™, its latest innovation in the company’s suite of online data management tools serving the life sciences industry. Built on top of the existing BioPharm Clinical platform, SiteSurvey will significantly improve feasibility teams’ ability to identify, analyze and manage critical data relevant to finding ideal sites for clinical trials.
“We developed SiteSurvey to make the site feasibility process faster and smarter,” said Ruth McHenry, managing director of Infinata, BioPharm Clinical’s parent company. “SiteSurvey eliminates a lot of the data migration and the repetition that currently bogs down the feasibility process, and the system also takes care of a lot of the heavy lifting on the analysis side -- by comparing each site’s responses to the ideal answers you’re looking for and developing an overall rank for each site.”
SiteSurvey’s powerful technology addresses the challenges that feasibility teams regularly face by taking their existing sites and investigators and matching them to the data contained within BioPharm Clinical -- to create a unique superset of clinical sites and investigators for each user. SiteSurvey also stores all investigator responses; thereby avoiding duplication of questions they’ve previously been asked. SiteSurvey then delivers an individual rank and score for every survey answer – giving clinical operations managers insight into when and where to ideally conduct trials.
SiteSurvey provides additional in-depth analysis with Site Qualifier - a proprietary algorithm that scores sites based on survey results to provide an overview of the entire site landscape for a particular study.
A formal presentation on SiteSurvey, “Integrating Site Survey Management Tools into Your Clinical Trial Workflow,” will be given on Wednesday, February 6. All registered attendees of 2014 SCOPE are invited to attend.
BioPharm Clinical has established itself within the life sciences industry as an indispensable online tool for helping clinical operations and feasibility managers plan and conduct clinical trials. Drug trial sponsors and Contract Research Organizations (CROs) alike recognize BioPharm Clinical’s value as a data management, research and forecasting resource. SiteSurvey was developed to specifically tackle the challenges and burdens of managing the feasibility questionnaire process.
For more information about 2014 SCOPE or about SiteSurvey™, click here.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
